Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carsten Saft

Showing results (131-140 of 144) with videos related to

Pageof 15
Sort By:
Molecular Neurodegeneration|November 16, 2014
Increase of angiotensin II type 1 receptor auto-antibodies in Huntington's diseaseDe-Hyung Lee, Harald Heidecke, Alexandra Schröder, et al.
Journal of Neurology|June 6, 2026
Virtual reality-based oculography detects internuclear ophthalmoplegia in multiple sclerosis and other neurological disordersEmilie Reuter, Justus Luerweg, Melina Katsimpoura, et al.
Neurology. Genetics|December 13, 2021
Transcript-Specific Loss-of-Function Variants in <i>VPS16</i> Are Enriched in Patients With DystoniaJoohyun Park, Annemarie Reilaender, Jan N Petry-Schmelzer, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 14, 2024
The frequency and clinical impact of synonymous HTT loss-of-interruption and duplication-of-interruption variants in a diverse HD cohortJessica Dawson, Chris Kay, Hailey Findlay Black, et al.
Brain Pathology (Zurich, Switzerland)|February 25, 2026
The DNA/RNA autophagy protein SIDT2 as a novel neuropathological hallmark in Huntington diseaseSanaz Gabery, Sofia Bergh, Chrisovalantou Huridou, et al.
Plos One|July 7, 2015
Exploring Genetic Factors Involved in Huntington Disease Age of Onset: E2F2 as a New Potential Modifier GeneLeire Valcárcel-Ocete, Gorka Alkorta-Aranburu, Mikel Iriondo, et al.
Nature Medicine|September 5, 2025
Pridopidine in early-stage manifest Huntington's disease: a phase 3 trialRalf Reilmann, Andrew Feigin, Anne E Rosser, et al.
The New England Journal of Medicine|May 7, 2019
Targeting Huntingtin Expression in Patients with Huntington's DiseaseSarah J Tabrizi, Blair R Leavitt, G Bernhard Landwehrmeyer, et al.
British Journal of Clinical Pharmacology|September 17, 2014
An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's diseaseSigurd D Süssmuth, Salman Haider, G Bernhard Landwehrmeyer, et al.
Human Molecular Genetics|August 8, 2020
Patterns of CAG repeat instability in the central nervous system and periphery in Huntington's disease and in spinocerebellar ataxia type 1Ricardo Mouro Pinto, Larissa Arning, James V Giordano, et al.
Pageof 15

Showing results (131-140 of 144) with videos related to

Sort By:
Pageof 15
Molecular Neurodegeneration|November 16, 2014
Increase of angiotensin II type 1 receptor auto-antibodies in Huntington's diseaseDe-Hyung Lee, Harald Heidecke, Alexandra Schröder, et al.
Journal of Neurology|June 6, 2026
Virtual reality-based oculography detects internuclear ophthalmoplegia in multiple sclerosis and other neurological disordersEmilie Reuter, Justus Luerweg, Melina Katsimpoura, et al.
Neurology. Genetics|December 13, 2021
Transcript-Specific Loss-of-Function Variants in <i>VPS16</i> Are Enriched in Patients With DystoniaJoohyun Park, Annemarie Reilaender, Jan N Petry-Schmelzer, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 14, 2024
The frequency and clinical impact of synonymous HTT loss-of-interruption and duplication-of-interruption variants in a diverse HD cohortJessica Dawson, Chris Kay, Hailey Findlay Black, et al.
Brain Pathology (Zurich, Switzerland)|February 25, 2026
The DNA/RNA autophagy protein SIDT2 as a novel neuropathological hallmark in Huntington diseaseSanaz Gabery, Sofia Bergh, Chrisovalantou Huridou, et al.
Plos One|July 7, 2015
Exploring Genetic Factors Involved in Huntington Disease Age of Onset: E2F2 as a New Potential Modifier GeneLeire Valcárcel-Ocete, Gorka Alkorta-Aranburu, Mikel Iriondo, et al.
Nature Medicine|September 5, 2025
Pridopidine in early-stage manifest Huntington's disease: a phase 3 trialRalf Reilmann, Andrew Feigin, Anne E Rosser, et al.
The New England Journal of Medicine|May 7, 2019
Targeting Huntingtin Expression in Patients with Huntington's DiseaseSarah J Tabrizi, Blair R Leavitt, G Bernhard Landwehrmeyer, et al.
British Journal of Clinical Pharmacology|September 17, 2014
An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's diseaseSigurd D Süssmuth, Salman Haider, G Bernhard Landwehrmeyer, et al.
Human Molecular Genetics|August 8, 2020
Patterns of CAG repeat instability in the central nervous system and periphery in Huntington's disease and in spinocerebellar ataxia type 1Ricardo Mouro Pinto, Larissa Arning, James V Giordano, et al.
Pageof 15